Healthcare

CytoDyn (OTC: CYDY) Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV

FDA Previously Granted Rolling Review for BLA VANCOUVER, Washington, Mar 18, 2019 – CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential […]

Newsmakers

Medicine Man Technologies, Inc., (OTC: MDCL) to Present at Sidoti & Company,Spring 2019 Conference

DENVER, March 21, 2019 -Medicine Man Technologies, Inc. (otcqx:MDCL) (“Medicine Man Technologies” or “Company”), a rapidly growing, vertically integrated cannabis operator, today announced it will be presenting at the Sidoti & Company, LLC, Spring 2019 […]

Healthcare

CytoDyn (OTC: CYDY)Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)

VANCOUVER, Washington, March 11, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that leronlimab (PRO 140), […]

Consumer

Nightfood Ice Cream (OTC: NGTF) Expanding Distribution to Sixteen States; Second Production Run This Week, Initial Feedback is Strong

Tarrytown, NY, March 11, 2019 — Nightfood, Inc. (otcqb:NGTF), the innovative company solving America’s $50 billion-dollar nighttime snacking problem, has announced that the second production run of Nightfood ice cream will begin this week, and […]

Healthcare

FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

VANCOUVER, Washington, March 04, 2019 — CytoDyn Inc. (otc.qb:CYDY), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the FDA has reviewed […]

Healthcare

CytoDyn (OTC: CYDY) to Present New Data from Study of Investigational HIV Therapy Leronlimab (PRO 140), a Long-Acting, Single-Agent Maintenance Therapy at CROI 2019

VANCOUVER, Washington, Feb. 27, 2019 — CytoDyn Inc. (OTC.QB: CYDY), a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that data from its study of leronlimab […]

Consumer

Nightfood (OTC: NGTF) Ice Cream Coupon Program Launches March 1st, Over 33,000 Consumer Sign-Ups to Date

Tarrytown, NY, Feb 28, 2019 – Nightfood, Inc. (OTC QB: NGTF), the innovative company solving America’s $50 billion-dollar nighttime snacking problem, has announced that over 33,000 consumers across the country have already requested coupons for […]

Consumer

Nightfood (OTC: NGTF) Ice Cream Expands into California Through Distribution Partnership with Wonder Ice Cream of Santa Clara Adding 300 Independent Supermarkets; Highest Revenue Quarter in Company History

          TARRYTOWN, NY, Feb. 26, 2019  – Nightfood, Inc. (otcqb:NGTF), the innovative company solving America’s $50 billion-dollar nighttime snacking problem, has announced entry into the northern California market through a distribution […]

Healthcare

CytoDyn’s (OTC: CYDY) Leronlimab (PRO 140) reduces by more than 98% human breast cancer metastasis in mouse xenografts for over 6 weeks

Based on strong results in its pre-clinical animal study, CytoDyn files for Orphan Drug Designation for Triple-Negative Breast Cancer VANCOUVER, Washington, Feb 20, 2019 – CytoDyn Inc. (otc.qb:CYDY), a biotechnology company developing a novel humanized […]

Healthcare

CytoDyn (OTC: CYDY) Announces Productive Conference Call with FDA Regarding First BLA Submission for Leronlimab (PRO 140) Combination Therapy at 700 mg Dose

VANCOUVER, Washington, Feb 01, 2019 — Successful interim results in the 700 mg monotherapy arm prompted the FDA to allow CytoDyn to switch all remaining combination therapy patients from CD02-Extension study from 350 mg to […]

Newsmakers

FSD Pharma (OTC: FSDDF) Announces Signing of LOI with Solarvest to Develop and Test Pharma-Grade Cannabinoids out of Algae

PHARMA GRADE PROCESS COULD REDUCE THE PRODUCTION TIME FOR TARGETED CANNABINOID MOLECULE(S) FSD Pharma Inc. (“FSD Pharma”)(OTC: FSDDF)  and Solarvest BioEnergy Inc. (SVS) (“Solarvest”) ()Parties”), a technology company which has developed an algal-based flexible production platform […]

Mining & Metals

Cobalt 27 (OTC: CBLLF) Closes Royalties on Flemington Nickel-Cobalt Project and Nyngan Scandium Project in Australia

TORONTO, Jan. 18, 2019 – Cobalt 27 Capital Corp. (“Cobalt 27” or the “Company”) (TSXV: KBLT)(OTCQX: CBLLF)(FRA: 27O), a battery metals streaming and royalty company offering direct exposure to metals integral to electric vehicles and energy storage systems, today announced […]

Newsmakers

MedPharm Holdings Develops Innovative Cannabinoid Infused Dissolvable Oral Strip

Today MedPharm Holdings announced the successful formulation and development of micro-emulsified, cannabis infused, dissolvable thin strips “Melts,” powered with their proprietary Lipophilic Enhanced Absorption Formulation (LEAF) technology. The oral strip is unique in that it […]